Skip to main content

Advertisement

SpringerLink
Log in

Role of hypertension in the metabolic syndrome: Who is affected?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Hypertension is one of the components of the metabolic syndrome. The “deadly quartet,” as this syndrome is often referred to, also includes atherogenic dyslipidemia; hyperglycemia and/or insulin resistance (IR); and abdominal obesity. More than 47 million people in the United States have the metabolic syndrome, with a higher prevalence in certain ethnic groups. This is expected to rise significantly in the future, in large part due to the obesity epidemic. The relative contribution of each of the constituents of this syndrome varies according to the population in which it occurs, but the significance of these variations is not known. In this article, we review the role of hypertension in the metabolic syndrome, its complex association with obesity and IR, and its disproportionate contribution to the syndrome in certain ethnic groups (specifically US blacks).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Reaven GM: Abnormal lipoprotein metabolism in non-insulin-dependent diabetes mellitus: pathogenesis and treatment. Am J Med 1987, 83:31–40.

    Article  PubMed  CAS  Google Scholar 

  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment o f High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2496. This executive summary contains treatment recommendations derived from the evidence-based full ATP III report. The document draws attention to the importance of the metabolic syndrome and provides a working definition of this syndrome for the first time.

    Article  Google Scholar 

  3. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359. Using the Third National Health and Nutrition Examination Survey sample of the US population, this analysis shows that the prevalence of the metabolic syndrome, as defined by the ATP III Report, is high in US adults. Its higher prevalence among some ethnic groups is also presented.

    Article  PubMed  Google Scholar 

  4. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease, among NHANES III participants age 50 years and older. Diabetes 2003, 52:121–214.

    Article  Google Scholar 

  5. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.

    Article  PubMed  CAS  Google Scholar 

  6. Trevisan M, Liu J, Bahsas FB, Menotti A: Syndrome X and mortality: a population-based study. Am J Epidemiol 1998, 148:958–966.

    PubMed  CAS  Google Scholar 

  7. Ferrannini E, Buzzigoli G, Bonaonna R, et al.: Insulin resistance in essential hypertension. N Engl J Med 1987, 317:350–357.

    Article  PubMed  CAS  Google Scholar 

  8. Grundy SM: Inflammation, hypertension, and the metabolic syndrome. JAMA 2003, 290:3000–3002.

    Article  PubMed  CAS  Google Scholar 

  9. Ohlson LO, Larsson B, Svardsudd K, et al.: The influence of body fat distribution on the incident of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985, 34:1055–1058.

    Article  PubMed  CAS  Google Scholar 

  10. Sironi AM, Gastaldelli A, Mari A, et al.: Visceral fat in hypertension influence on insulin resistance and B-cell function. Hypertension 2004, 44:127–133.

    Article  PubMed  CAS  Google Scholar 

  11. Wolk R, Shamsuzzaman AS, Somers V: Obesity, sleep apnea and hypertension. Hypertension 2003, 42:1067–1074. Nice review of the evidence supporting the role of obstructive sleep apnea as an important player in the association between obesity and hypertension.

    Article  PubMed  CAS  Google Scholar 

  12. Landsberg L: Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. N Engl J Med 1996, 61:1081–1090.

    Google Scholar 

  13. Poirier P, Lemieux I, Mauriege P, et al.: The Quebec Health Survey. Hypertension 2005, 45:363–367.

    Article  PubMed  CAS  Google Scholar 

  14. Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and the sympathetic nervous system. Am J Hypertens 2001, 14:103s-111s.

    Article  PubMed  CAS  Google Scholar 

  15. Hall JE, Crook ED, Jones DW, et al.: Mechanism of obesityassociated cardiovascular and renal disease. Am J Med Sci 2002, 324:127–137.

    Article  PubMed  Google Scholar 

  16. Rahmouni K, Correia MLG, Haynes WG, et al.: Obesity-associated hypertension. Hypertension 2005, 45:9–14. This paper provides a current and detailed review of some highlights on advances in understanding the pathophysiology of obesity. Emphasis on mechanisms that underline the obesity-hypertension relationship is provided.

    Article  PubMed  CAS  Google Scholar 

  17. Haynes WG, Morgan DA, Djalai A, et al.: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999, 17:1949–1953.

    Article  Google Scholar 

  18. Hall JE, Kuo JJ, da Silva AA, et al.: Obesity-associated hypertension and kidney disease. Curr Opin Nephrol 2003, 12:195–200.

    Article  CAS  Google Scholar 

  19. Beltowski J, Wojcicka G, Marciniak A, et al.: Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci 2004, 74:2987–3000.

    Article  PubMed  CAS  Google Scholar 

  20. Iwashima Y, Katsuya T, Ishikawa K, et al.: Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318–1323.

    Article  PubMed  CAS  Google Scholar 

  21. Kojima S, Funahashi T, Sakamoto T, et al.: The variations of plasma concentrations of a novel adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 2003, 89:667–668.

    Article  PubMed  CAS  Google Scholar 

  22. Poykko SM, Kellokoski E, Horkko S, et al.: Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003, 52:2546–2553.

    Article  PubMed  Google Scholar 

  23. Sharma AM, Janke J, Gorzelniak K, et al.: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609–611.

    Article  PubMed  CAS  Google Scholar 

  24. Masuzaki H, Yamamoto H, Kenyon CJ, et al.: Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003, 112:83–90.

    Article  PubMed  CAS  Google Scholar 

  25. Nielsen S, Halliwill JR, Joyner MJ, et al.: Vascular response to angiotensin II in upper-body obesity. Hypertension 2004, 44:436–441.

    Article  CAS  Google Scholar 

  26. Steinberg HO, Chaker H, Leaming R, et al.: Obesity hypertension is related more to insulin’s fatty acid than glucose action. Hypertension 1996, 97:2601–2610.

    CAS  Google Scholar 

  27. Egan BM, Hennes MM, Stepniakowski K, et al.: Obesity hypertension is related more to insulin’s fatty acid than glucose action. Hypertension 1996, 27:7223–7728.

    Google Scholar 

  28. Goodfriend TL, Calhoun DA: Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004, 43:518–524.

    Article  PubMed  CAS  Google Scholar 

  29. de Paula RB, da Silva AA, Hall JE: Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41–47.

    Article  PubMed  CAS  Google Scholar 

  30. Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesity: associated cardiovascular and renal disease. Am J Med Sci 2002, 323:127–137.

    Article  Google Scholar 

  31. Hengegar JR, Bigle SA, Hengegar LK, et al.: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001, 12:1211–1217.

    Google Scholar 

  32. Dwyer TM, Banks SA, Alonso-Galicia M, et al.: Distribution of renal medullary hyaluronan in lean and obese rabbits. Kidney Int 2000, 58:721–729.

    Article  PubMed  CAS  Google Scholar 

  33. Nieto FJ, Young TB, Lind BK, et al.: Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 2000, 283:1829–1836. This study represents one of the largest cross-sectional studies to date documenting the association between sleep-disordered-breathing and hypertension in apparently healthy, middle-aged and older adults of diverse ethnic backgrounds and different sexes. This study stresses the significantly increased prevalence of hypertension with increasing measures of sleep-disordered breathing.

    Article  PubMed  CAS  Google Scholar 

  34. Fournier AM, Gadia MT, Kubrusly DB, et al.: Blood pressure, insulin, and glycemia in nondiabetic subjects. Am J Med 1986, 80:861–864.

    Article  PubMed  CAS  Google Scholar 

  35. Donahue RP, Orchard TJ, Becker DJ, et al.: Sex differences in the coronary heart disease risk profile: a possible role for insulin: the Beaver County study. Am J Epidemiol 1987, 125:650–657.

    PubMed  CAS  Google Scholar 

  36. Skarfors ET, Lithell HO, Selinus I: Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens 1991, 9:217–223.

    Article  PubMed  CAS  Google Scholar 

  37. Lissner L, Bengtsson C, Lapidus L, et al.: Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992, 20:797–801.

    PubMed  CAS  Google Scholar 

  38. Taittonen I, Uhari M, Nuutinen M, et al.: Insulin and blood pressure among healthy children. Am J Hypertens 1996, 9:193–199.

    Article  Google Scholar 

  39. Raitakari OT, Porkka KVK, Ronnemaa T, et al.: The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. Diabetologia 1995, 38:1042–1050.

    Article  PubMed  CAS  Google Scholar 

  40. Liese AD, Mayer-Davis EJ, Chambless LE, et al.: Elevated fasting insulin predicts incident hypertension: the ARIC study. J Hypertens 1999, 17:1169–1177.

    Article  PubMed  CAS  Google Scholar 

  41. Saad MF, Lillioja S, Nyomba BL, et al.: Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1993, 324:733–9.

    Article  Google Scholar 

  42. Saad MF, Rewers M, Selby J, et al.: Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension 2004, 43:1324–1331.

    Article  PubMed  CAS  Google Scholar 

  43. Collins VR, Dowse GK, Finch CF, Zimmet PZ: An inconsistent relationship between insulin and blood pressure in three Pacific Island populations. J Clin Epidemiol 1990, 43:1369–1378.

    Article  PubMed  CAS  Google Scholar 

  44. Reaven GM: Insulin resistance/compensatory hyperinsulinimia, essential hypertension and cardiovascular disease. J Clin Endocrinol Metab 2003, 88:2399–2403. Excellent review and discussion of the role of insulin resistance and compensatory hyperinsulinemia in the pathogenesis of essential hypertension. Their roles in the development of cardiovascular disease in patients with hypertension is also analyzed.

    Article  PubMed  CAS  Google Scholar 

  45. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374–381.

    Article  PubMed  CAS  Google Scholar 

  46. Wheatcrosft SB, Williams IL, Shah AM, Kearney MT: Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003, 20:255–268.

    Article  Google Scholar 

  47. Avid A, Gardner J: Racial differences in ion regulation and their possible links to hypertension in blacks. Hypertension 1989, 14:585–589.

    Google Scholar 

  48. Falkner B, Kushner H, Levison S, Canessa M: Albuminuria in association with insulin and sodium-lithium countertransport in young African Americans with borderline hypertension. Hypertension 1995, 25:1315–1321.

    PubMed  CAS  Google Scholar 

  49. Carnethon MR, Loria CM, Hill JO, et al.: Risk factors for the metabolic syndrome. The Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985–2001. Diabetes Care 2004, 27:2707–2715.

    Article  PubMed  Google Scholar 

  50. Frontini MG, Srinivasan SR, Elkasabany A, Berenson GS: Distribution and cardiovascular risk correlates of serum triglycerides in young adults from a biracial community. The Bogalusa Heart Study. Atherosclerosis 2001, 158:201–209.

    Article  Google Scholar 

  51. Jessepen J, Ole Heim H, Svadicani P, Gynterberg F: Low triglycerides-high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001, 161:361–366.

    Article  Google Scholar 

  52. Davis TME, Cull CA, Holman RR: Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes. Diabetes Care 2001, 24:1116–1174.

    Google Scholar 

  53. Sesso HD, Baring JE, Rifai N, et al.: C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945–2951. A positive relationship between increased serum levels of C-reactive protein and the risk for development of incident hypertension in participants of the Women’s Health Study, a large, prospective, epidemiologic cohort, is reported. More than 20,000 women were followed prospectively for 7.8 years during which time about one fourth of them acquired elevated blood pressure. Those with the higher levels of C-reactive protein were more likely to develop hypertension. This study supports the role of inflammation as a marker for vascular dysfunction and subsequent risk for hypertension.

    Article  PubMed  CAS  Google Scholar 

  54. King DE, Egan BM, Mainous III AG, Geesey ME: Elevation of Creactive protein in people with prehypertension. J Clin Hypertens 2004, 6:562–568.

    CAS  Google Scholar 

  55. Jialal I, Devaraj S, Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004, 44:6–11.

    Article  PubMed  CAS  Google Scholar 

  56. Tsikouris JP, Suarez JA, Simoni JS, et al.: Exploring the effects of ACE inhibitor, tissue penetration on vascular inflammative following acute myocardial infarction. Coronary Artery Dis 2004, 15:211–217.

    Google Scholar 

  57. Curtin PD: The slavery hypothesis for hypertension among African Americans: the historical evidence. Am J Public Health 1992, 82:1681–1686.

    Article  PubMed  CAS  Google Scholar 

  58. Wolz M, Cutler J, Rocella EJ, et al.: Statement from the National High Blood Pressure Education Program: prevalence of hypertension. Am J Hypertens 2000, 13:103–104.

    Article  PubMed  CAS  Google Scholar 

  59. Park YW, Zhu S, Polaniappan L, et al.: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2003, 163:427–436.

    Article  PubMed  Google Scholar 

  60. He J, Kag MJ, Caballero B, et al.: Plasma insulin levels and incidence of hypertension in African Americans and whites. Arch Intern Med 1999, 159:498–503.

    Article  PubMed  CAS  Google Scholar 

  61. Kountz D: Hypertension in ethnic population tailoring treatments. Clin Cornerstone 2004, 6:39–48.

    Article  PubMed  Google Scholar 

  62. Jha P, Enas EA, Yusuf S: Coronary artery disease in Asian Indians, prevalence and risk factors. Asian Am Pac Isl J Health 1993, 1:163–175.

    PubMed  Google Scholar 

  63. Ramachandran A, Snehalatha C, Latha E, et al.: Clustering of cardiovascular risk factors in urban Asian Indians. Diabetes Care 1998, 21:967–971.

    Article  PubMed  CAS  Google Scholar 

  64. Singh RB, Niaz MA, Ghosh S, et al.: Epidemiological study of coronary artery disease and its risk factors in an elderly urban population of north India. J Am Coll Nutr 1995, 14:628–634.

    PubMed  CAS  Google Scholar 

  65. Narkiewicz K, Phillips BG, Kator M, et al.: Gender-selective interactions between aging, blood pressure, and sympathetic nerve activity. Hypertension 2005, 45:522–525. This elegant study shows gender-selective interactions between aging, blood pressure, and sympathetic nerve activity in a group of normal white adult subjects. They found that aging is accompanied by a greater increase in sympathetic traffic, in women, independent of menopausal status, than in men, as measured by muscle sympathetic nerve activity. They further hypothesize that these findings may in turn explain the more marked influence of age on blood pressure and cardiovascular disease in women.

    Article  PubMed  CAS  Google Scholar 

  66. Grundy SM, Hansen B, Smith SC Jr, et al.: Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation 2004, 109:551–556. This report, sponsored by the AHA and NHLBI and co-sponsored by the ADA, provides consensus recommendations for the diagnosis and clinical management of the metabolic syndrome. The rationale for cut-points in interventional strategies is reviewed. The report also underlines important unresolved issues that will need attention in future research.

    Article  PubMed  Google Scholar 

  67. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with life style intervention or metformin. N Engl J Med 2002, 346:393–403.

    Article  Google Scholar 

  68. Van Gaol LF, Rissanen AM, Scheen AJ, et al.: RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 2005, 365:1389–1397.

    Article  CAS  Google Scholar 

  69. Wang TD, Chen WJ, Lin JW, et al.: Effects of rosiglitazone on endothelial function, C-reactive protein, and component of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004, 93:362–365.

    Article  PubMed  CAS  Google Scholar 

  70. Szapary P, Bloedon L, Samaha FF, et al.: The effects of pioglitazone on lipoproteins in non-diabetics with metabolic syndrome: results from a randomized controlled trial. Program and abstracts of the 65th Scientific Session of the American Diabetes Association; San Diego, CA. June10–14, 2005, Abstract 963-P.

  71. Kim DK, Young JA, Park M, et al.: The effects of combination therapy with exercise and fenofibrate for the metabolic syndrome in rats. Program and abstracts of the 65th Scientific Session of the American Diabetes Association; San Diego, CA. June 10–14, 2005, Abstract 1794.

  72. Collins R, Peto R, Mac Mahon S, et al.: Blood pressure, stroke and coronary heart disease. Part 2: Short term reductions in blood pressure; overview of randomized drug trials in their epidemiological context. Lancet 1990, 335:827–838.

    Article  PubMed  CAS  Google Scholar 

  73. 73.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:1981–1997. This study represents one of the first studies to compare the long-term metabolic effects of a commonly used low-dose diuretic-based antihypertensive regimen (alone or in combination with a β-blocker) with that of an ACEI-based regimen (alone or in combination with a calcium channel blocker) in newly diagnosed hypertensive patients. This study showed that the commonly used low-dose diuretic alone or in combination with a β-blocker was associated with an aggravated metabolic profile.

    Article  Google Scholar 

  74. Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003, 21:1563–1574. This study was designed to determine whether the occurrence of fatal coronary heart disease or nonfatal MI differed with either one of three different antihypertensive regimens (CCB vs ACEI vs diuretic). Of particular importance, the study adequately represented different ethnic/ racial groups of both genders. Overall, the study found no regimen to be superior in reducing primary end points or in increasing survival over a mean follow up of 4.9 years. Differences in secondary outcomes were noted.

    Article  PubMed  CAS  Google Scholar 

  75. Verdecchia P, Gianpaolo R, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963–969.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Division, University of Rochester, Box 679, 14642, Rochester, NY, USA

    Gladys Velarde MD & Bradford C. Berk MD, PhD

Authors
  1. Gladys Velarde MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bradford C. Berk MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Velarde, G., Berk, B.C. Role of hypertension in the metabolic syndrome: Who is affected?. Current Science Inc 7, 418–426 (2005). https://doi.org/10.1007/s11906-005-0036-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-005-0036-x

Keywords

Search

Navigation